Abstract
Noninvasive quantitative imaging of beta-cells can provide information on changes in cellular transporters, receptors, and signaling proteins that may affect function and/or loss of mass, both of which contribute to the loss of insulin secretion and glucose regulation of patients with type 1 or type 2 diabetes (T1D/T2D). We have developed and optimized the use of two positron emission tomography (PET) radioligands, [18F]FP-(+)-DTBZ and [11C](+)-PHNO, targeting beta-cell VMAT2 and dopamine (D2/D3) receptors, respectively. Here we describe our optimized methodology for the clinical use of these two tracers for quantitative PET imaging of beta-cell biomarkers in vivo. We also briefly discuss our previous results and their implications and value towards extending the use of PET radioligand beyond the original goal of quantitative imaging of beta-cell mass to the potential to provide insight into the biology of beta-cell loss of mass and/or function and to evaluate the efficacy of therapeutics to prevent or restore functional beta-cell mass.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Anlauf M, Eissele R, Schäfer MK-H, Eiden LE, Arnold R, Pauser U et al (2003) Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 51:1027–1040
Maffei A, Liu Z, Witkowski P, Moschella F, Pozzo GDEL, Liu E et al (2004) Identification of tissue-restricted transcripts in human islets. Endocrinology 145:4513–4521
Saisho Y, Harris PE, Butler AE, Galasso R, Gurlo T, Rizza RA et al (2008) Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 39:543–551
Freeby M, Ichise M, Harris PE (2012) Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Islets 4:393–397
Kung M-P, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E et al (2008) In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 49:1171–1176
Eriksson O, Jahan M, Johnström P, Korsgren O, Sundin A, Halldin C et al (2010) In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol 37:357–363
Normandin MD, Petersen KF, Ding Y-S, Lin S-F, Naik S, Fowles K et al (2012) In vivo imaging of endogenous pancreatic beta-cell mass in healthy and type 1 diabetic subjects using 18f-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 53:908–916
Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N et al (2009) 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50:382–389
Bini J, Naganawa M, Nabulsi NB, Huang YH, Ropchan J, Lim K et al (2018) Evaluation of PET brain radioligands for imaging pancreatic β-cell mass: potential utility of 11 C-PHNO. J Nucl Med 59:1249–1254
Korner J, Cline GW, Slifstein M, Barba P, Rayat GR, Febres G et al (2019) A role for foregut tyrosine metabolism in glucose tolerance. Mol Metab 23:37–50
Ustione A, Piston DW, Harris PE (2013) Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet. Mol Endocrinol 27:1198–2107
Bini J, Sanchez-Rangel E, Gallezot J-D, Naganawa M, Nabulsi NB, Lim K et al (2020) PET imaging of pancreatic dopamine D3/D2 receptor density with 11 C (+)-PHNO in Type-1 diabetes mellitus. J Nucl Med 61:570–576
Eriksson O, Espes D, Selvaraju RK, Jansson E, Antoni G, Sorensen J et al (2014) Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 63:3428–3437
Brom M, Woliner-Van Der Weg W, Joosten L, Frielink C, Bouckenooghe T, Rijken P et al (2014) Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin. Diabetologia 57:950–959
Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC (2013) β-Cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 36:111–117
Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM et al (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53:690–698
Oram RA, Jones AG, Besser REJ, Knight BA, Shields BM, Brown RJ et al (2014) The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 57:187–191
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603–613
Cline GW, Naganawa M, Chen L, Chidsey K, Carvajal-gonzalez S, Pawlak S et al (2018) Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Diabetologia 61:2598–2607
Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150:1223–1234
Diedisheim M, Oshima M, Albagli O, Huldt CW, Ahlstedt I, Clausen M et al (2018) Modeling human pancreatic beta cell dedifferentiation. Mol Metab 10:74–86
Pajvani UB, Accili D (2015) The new biology of diabetes. Diabetologia 58:2459–2468
Naganawa M, Lin S-F, Lim K, Labaree D, Ropchan J, Harris P et al (2016) Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of (18)F-FP-DTBZ in baboons. Nucl Med Biol 43:743–751
Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6, 10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153–4160
Söderberg M (2016) Overview, practicaltips and potential pitfalls of using automatic exposure control in CT: siemens CARE Dose 4D. Radiat Prot Dosimetry 169:84–91
Naganawa M, Lim K, Nabulsi NB, Lin S-f, Labaree D, Ropchan J et al (2018) Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of [18F]FP-DTBZ in healthy subjects and patients with type 1 diabetes. Mol Imaging Biol 20:835–485
Mizrahi R (2010) Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J Nucl Med 51:496–498
Cline GW, McCarthy TJ, Carson RE, Calle RA (2018) Clinical and scientific value in the pursuit of quantification of beta cells in the pancreas by PET imaging. Diabetologia 61:2671–2673
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840
Van Der Weerdt AP, Klein LJ, Visser CA, Visser FC, Lammertsma AA (2002) Use of arterialised venous instead of arterial blood for measurement of myocardial glucose metabolism during euglycaemic-hyperinsulinaemic clamping. Eur J Nucl Med Mol Imaging 29:663–669
Yu Y, Chan C, Ma T, Liu Y, Gallezot JD, Naganawa M et al (2016) Event-by-event continuous respiratory motion correction for dynamic PET imaging. J Nucl Med 57:1084–1090
Ren S, Jin X, Chan C, Jian Y, Mulnix T, Liu C et al (2017) Data-driven event-by-event respiratory motion correction using TOF PET list-mode centroid of distribution. Phys Med Biol 62:4741–4755
Lu Y, Gallezot JD, Naganawa M, Ren S, Fontaine K, Wu J et al (2019) Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. Phys Med Biol 64:065002
Acknowledgements
This work was supported by a training grant from the NIDDK (K01DK118005).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bini, J., Carson, R.E., Cline, G.W. (2023). Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo. In: Moore, A., Wang, P. (eds) Type-1 Diabetes. Methods in Molecular Biology, vol 2592. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2807-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2807-2_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2806-5
Online ISBN: 978-1-0716-2807-2
eBook Packages: Springer Protocols